MedTrace Logo

Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission

NCT00101140 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-10-19

No results posted yet for this study

Summary

RATIONALE: A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving total-body irradiation together with fludarabine, thiotepa, and antithymocyte globulin before transplant may stop this from happening.

PURPOSE: This phase II trial is studying how well a donor stem cell transplant works in treating patients with acute myeloid leukemia in remission.

Conditions

  • Adult Acute Erythroid Leukemia
  • Adult Acute Monoblastic and Acute Monocytic Leukemia
  • Adult Acute Myeloid Leukemia

Interventions

DRUG

anti-thymocyte globulin

DRUG

fludarabine phosphate

DRUG

thiotepa

PROCEDURE

biological therapy

PROCEDURE

bone marrow ablation with stem cell support

PROCEDURE

chemotherapy

PROCEDURE

non-specific immune-modulator therapy

PROCEDURE

peripheral blood stem cell transplantation

PROCEDURE

radiation therapy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Eastern Cooperative Oncology Group

    lead NETWORK

Principal Investigators

  • Mark R. Litzow, MD · Mayo Clinic

  • Jacob M. Rowe, MD · Rambam Health Care Campus

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00101140 on ClinicalTrials.gov